Business UpdateMay 12, 2026, 07:32 AM
Harvard Bioscience Refinances Debt, Consolidates Manufacturing
AI Summary
Harvard Bioscience announced significant strategic initiatives, including a debt refinancing that extends maturity to 2029 and reduces annual debt service by $3 million. The company is also undergoing a manufacturing consolidation, closing its Holliston, MA plant by Q1 2027, which is projected to improve adjusted EBITDA by $3 million in 2027 and $4 million from 2028 onwards. These actions are part of a broader strategic direction under new leadership, aiming to accelerate drug development through human-relevant translational tools. The company reported 1Q26 revenue of $20.8 million and provided positive FY26 guidance for revenue and adjusted EBITDA growth.
Key Highlights
- Debt refinancing extended maturity to 2029, reducing annual debt service by $3 million.
- Strategic manufacturing consolidation includes closing the Holliston, MA plant by Q1 2027.
- Manufacturing consolidation is expected to improve adjusted EBITDA by $3 million in 2027 and $4 million from 2028 onwards.
- John Duke was appointed CEO in July 2025, and Mark Frost became permanent CFO in March 2026.
- Reported 1Q26 total revenue of $20.8 million, a 5% decrease from $21.8 million in 1Q25.
- Provided FY26 revenue growth guidance of 2-4% and adjusted EBITDA growth of 6-10%.
- Reported 54% recurring revenue in FY25, with a clear path to 60% recurring revenue.
- 1Q26 GAAP diluted loss per share was $(0.77) and adjusted diluted loss per share was $(0.33).